Second-Generation Tyrosine Kinase Inhibitors In Chronic Myelogenous Leukemia

Second-Generation Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia

CML: Considering Second-Generation TKIs

Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia

VJHemOnc – Video Journal of Hematology & HemOnc

Chronic Myeloid Leukemia (CML) - Treatment - Tyrosine Kinase (TK) Inhibitors

Medicosis Perfectionalis

Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Erba on Second-Generation TKIs for Chronic Phase CML

Adverse Events of Second-Generation TKIs Used in Treating CML

Targeted Oncology

Selecting a Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia Case Study

Upfront Treatment in Chronic Myeloid Leukemia (CML)

Benefits of second generation TKIs for CML in the frontline

VJHemOnc – Video Journal of Hematology & HemOnc

Case 3: Selecting Between TKI Inhibitors

Targeted Oncology

The current standard of care in CML and insights into the use of first- and second-generation TKIs

VJHemOnc – Video Journal of Hematology & HemOnc

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia

Ponatinib in chronic-phase CML patients with prior second generation TKI exposure

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Pamela Crilley on Imatinib and Second Generation TKIs

Targeted Oncology

Comparing Frontline Therapies for the Treatment of Chronic Myeloid Leukemia

Targeted Oncology

BCR-ABL1-Targeted TKIs in Treatment of CML

Targeted Oncology

Understanding the cause of TKI resistance to improve management strategies in CML

VJHemOnc – Video Journal of Hematology & HemOnc

Treating the Newly Diagnosed Patient With Chronic Myeloid Leukemia

Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line setting

VJHemOnc – Video Journal of Hematology & HemOnc